

**LIBERIA**  
**Support for Inactivated Polio Vaccine (IPV)**

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Liberia			
<b>2. Grant number(s):</b> 1518-LBR-25c-X/15-LBR-08h-Y			
<b>3. Date of Decision Letter:</b> 14 December 2017			
<b>4. Date of the Partnership Framework Agreement:</b> 19 August 2013			
<b>5. Programme title:</b> NVS, IPV routine			
<b>6. Vaccine type:</b> Inactivated Polio Vaccine (IPV)			
<b>7. Requested product presentation and formulation of vaccine<sup>1</sup>:</b> Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID			
<b>8. Programme duration<sup>2</sup>:</b> 2015 - 2018			
<b>9. Indicative Programme Budget:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <i>Please note that endorsed or approved amounts for 2019 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i>			
	2015-2017	2018	Total <sup>3</sup>
Routine Programme (US\$)	84,568 <sup>4</sup>	189,500	274,068
<b>10. Vaccine introduction grant / Product switch grant:</b> US\$125,000 already disbursed to Liberia on 25 July 2014			

<sup>1</sup> Please refer to section 18 for additional information on IPV presentation.

<sup>2</sup> This is the entire duration of the Programme.

<sup>3</sup> This is the total amount endorsed by Gavi for 2015 to 2018.

<sup>4</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

**11. Gavi Indicative Annual Amounts:** (subject to the terms of the Partnership Framework Agreement, if applicable)<sup>5</sup>

<b>Number of vaccines to be purchased with Gavi funds</b>	<b>2018</b>
IPV Routine Programme (doses)	228,000
Annual Amounts (US\$)	189,500

For information and reference, the related Injection Safety Devices to be purchased under Gavi funds for 2018 shall be included in a separate Decision Letter (Grant number: 17-LBR-32a-X; 18-LBR-32a-X; 19-LBR-32a-X; 20-LBR-32a-X):

<b>New Vaccine Support (NVS), Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID,Routine</b>	<b>2018</b>
Number of AD syringes	16,700
Number of re-constitution syringes	0
Number of safety boxes	175
Annual Amounts for injection safety devices for Vaccine (US\$)	1,000

**12. Procurement agency:** UNICEF

**13. Self-procurement:** Not Applicable

**14. Co-financing obligations:** Not applicable

Gavi's usual co-financing requirements do not apply to IPV. However, Liberia is encouraged to contribute to vaccine and/or supply costs for IPV.

**15. Operational support for catch-up campaigns:** Not applicable

<sup>5</sup> This is the amount that Gavi has approved.

**16. Additional reporting requirements:**

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

**17. Financial clarifications:** Not Applicable

**18. Other conditions:**

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

If Liberia envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Liberia.

On behalf of Gavi



Hind Khatib-Othman  
Managing Director, Country Programmes  
14 December 2017

## LIBERIA Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Liberia					
<b>2. Grant number:</b> 1820-LBR-12d-X /13-LBR-08c-Y					
<b>3. Date of Decision Letter:</b> 14 December 2017					
<b>4. Date of the Partnership Framework Agreement:</b> 19 August 2013					
<b>5. Programme title:</b> New Vaccine Support (NVS), Pneumococcal Routine					
<b>6. Vaccine type:</b> Pneumococcal					
<b>7. Requested product presentation and formulation of vaccine:</b> Pneumococcal (PCV13), 1 dose per vial, LIQUID, Pneumococcal (PCV13), 4 doses per vial, LIQUID					
<b>8. Programme duration<sup>1</sup>:</b> 2013- -2020					
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)					
	2014-2017	2018	2019	2020	Total <sup>2</sup>
Programme Budget (US\$)	6,985,935 <sup>3</sup>	1,777,000	1,842,500	1,990,500	12,595,935
<b>10. Vaccine introduction grant (in US\$) / Product switch grant:</b> US\$ 155,000 already disbursed to Liberia on 18 November 2013.					
<b>11. Gavi Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>					
<b>Number of vaccines to be purchased with Gavi funds each year</b>	<b>2014-2017</b>	<b>2018</b>			
Pneumococcal Routine Programme (doses)		529,000			
Annual Amounts (US\$)	6,985,953 <sup>5</sup>	1,777,000			

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

For information and reference, the related Injection Safety Devices to be purchased under Gavi funds for 2018 shall be included in a separate Decision Letter (Grant number: 17-LBR-32a-X; 18-LBR-32a-X; 19-LBR-32a-X; 20-LBR-32a-X):

<b>New Vaccine Support (NVS), Pneumococcal (PCV13), 1 dose(s) per vial LIQUID,Routine</b>	<b>2018</b>
Number of AD syringes	563,500
Number of re-constitution syringes	
Number of safety boxes	6,200
Annual Amounts for injection safety devices for Vaccine (US\$)	26,000

**12. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

**13. Self-procurement:** Not applicable

**14. Co-financing obligations:** Reference code: 1820-LBR-12d-X-C  
According to the co-financing policy, the Country falls within the group Initial self-financing.  
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

<b>Number of vaccines to be purchased with Gavi funds each year</b>	<b>2018</b>	<b>2019</b>	<b>2020</b>
Number of vaccine doses	37,000	36,800	38,400
Value of vaccine doses (US\$)	112,521		
Total co-financing payments (US\$) (including freight)	113,500	113,000	117,500

**15. Operational support for campaigns:** Not applicable

<b>16. Additional reporting requirements:</b>	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
<b>17. Financial clarifications:</b> Not applicable	
<b>18. Other conditions:</b> Not applicable	

On behalf of Gavi



Hind Khatib-Othman  
Managing Director, Country Programmes  
14 December 2017

## LIBERIA Support for Pentavalent Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Liberia					
<b>2. Grant number:</b> 1820-LBR-04c-X					
<b>3. Date of Decision Letter:</b> 14 December 2017					
<b>4. Date of the Partnership Framework Agreement:</b> 19 August 2013					
<b>5. Programme title:</b> New Vaccine Support (NVS), Pentavalent Routine					
<b>6. Vaccine type:</b> Pentavalent					
<b>7. Requested product presentation and formulation of vaccine:</b> DTP-HepB-Hib, 10 dose(s) per vial, LIQUID					
<b>8. Programme duration<sup>1</sup>:</b> 2008 -2020					
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)					
	2008-2017	2018	2019	2020	Total <sup>2</sup>
Programme Budget (US\$)	10,,313 <sup>3</sup>	368,500	337,500	351,500	11,727,813
<b>10. Vaccine introduction grant (in US\$) / Product switch grant:</b> Not applicable					
<b>11. Gavi Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>					
<b>Number of vaccines to be purchased with Gavi funds each year</b>	<b>2008-2017</b>	<b>2018</b>			
Pentavalent Routine Programme (doses)		474,000			
Annual Amounts (US\$)	10,670,313 <sup>5</sup>	368,500			

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

For information and reference, the related Injection Safety Devices to be purchased under Gavi funds for 2018 shall be included in a separate Decision Letter (Grant number: 17-LBR-32a-X; 18-LBR-32a-X; 19-LBR-32a-X; 20-LBR-32a-X):

<b>New Vaccine Support (NVS), DTP-HepB-Hib, 1 dose(s) per vial, LIQUID</b>	<b>2018</b>
Number of AD syringes	567,400
Number of re-constitution syringes	
Number of safety boxes	6,250
Annual Amounts for injection safety devices for Vaccine (US\$)	26,000

**12. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

**13. Self-procurement:** Not applicable

**14. Co-financing obligations:** Reference code: 1820-LBR-04c-X-C  
According to the co-financing policy, the Country falls within the group Initial self-financing.  
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

<b>Number of vaccines to be purchased with Gavi funds each year</b>	<b>2018</b>	<b>2019</b>	<b>2020</b>
Number of vaccine doses	164,500	188,500	196,500
Value of vaccine doses (US\$)	123,286		
Total co-financing payments (US\$) (including freight)	128,000	133,500	139,000

**15. Operational support for campaigns:** Not applicable

<b>16. Additional reporting requirements:</b>	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
<b>17. Financial clarifications:</b> Not applicable	
<b>18. Other conditions:</b> Not applicable	

On behalf of Gavi



Hind Khatib-Othman  
Managing Director, Country Programmes  
14 December 2017

## LIBERIA

### Support for Yellow Fever Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Liberia					
<b>2. Grant number:</b> 1720-LBR-06b-X					
<b>3. Date of Decision Letter:</b> 14 December 2017					
<b>4. Date of the Partnership Framework Agreement:</b> 19 August 2013					
<b>5. Programme title:</b> NVS, Yellow Fever Routine					
<b>6. Vaccine type:</b> Yellow Fever					
<b>7. Requested product presentation and formulation of vaccine:</b> Yellow Fever, 10 dose(s) per vial, LYOPHILISED					
<b>8. Programme duration<sup>1</sup>:</b> 2001 -2020					
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)					
	2001-2017	2018	2019	2020	Total <sup>2</sup>
Programme Budget (US\$)	2,068,056 <sup>3</sup>	180,000	184,000	232,000	2,664,056
<b>10. Vaccine introduction grant (in US\$):</b> US\$ 100,000 disbursed on 11.2.2002					
<b>11. Gavi Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable): <sup>4</sup>					
<b>Number of vaccines to be purchased with Gavi funds each year</b>	<b>2001-2017</b>		<b>2018</b>		
Yellow Fever Routine Programme (doses)			156,400		
Annual Amounts (US\$)	US\$2,068,056 <sup>5</sup>		US\$180,000		

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

For information and reference, the related Injection Safety Devices to be purchased under Gavi funds for 2018 shall be included in a separate Decision Letter (Grant number: 17-LBR-32a-X; 18-LBR-32a-X; 19-LBR-32a-X; 20-LBR-32a-X):

<b>New Vaccine Support (NVS), Yellow Fever, 10 dose(s) per vial, LYOPHILISED,Routine</b>	<b>2018</b>
Number of AD syringes	158,700
Number of re-constitution syringes	20,900
Number of safety boxes	1,975
Annual Amounts for injection safety devices for Vaccine (US\$)	8,500

**12. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

**13. Self-procurement:** Not applicable

**14. Co-financing obligations: Reference code:** 1720-LBR-06b-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

<b>Number of vaccines to be purchased with Country funds each year</b>	<b>2018</b>	<b>2019</b>	<b>2020</b>
Number of vaccine doses	33,000	33,700	42,500
Value of vaccine doses (US\$)	35,244		
Total co-financing payments (US\$) (including freight)	38,000	39,000	49,000

**15. Operational support for campaigns:** Not applicable

<b>16. Additional reporting requirements:</b> Not applicable	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
<b>17. Financial clarifications:</b> Not applicable	
<b>18. Other conditions:</b> There is currently a global shortage in the supply of yellow fever vaccines. The number of doses and presentation are subject to availability. Gavi will inform the Government as soon as possible of any changes in doses and/or presentation from what has been communicated to Liberia.	

On behalf of Gavi



Hind Khatib-Othman  
Managing Director, Country Programmes  
14 December 2017

## LIBERIA Support for Rotavirus Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Liberia					
<b>2. Grant number:</b> 1720-LBR-13b-X/15-LBR-08b-Y					
<b>3. Date of Decision Letter:</b> 14 December 2017					
<b>4. Date of the Partnership Framework Agreement:</b> 19 August 2013					
<b>5. Programme title:</b> New Vaccine Support (NVS), Rotavirus Routine					
<b>6. Vaccine type:</b> Rotavirus					
<b>7. Requested product presentation and formulation of vaccine:</b> Rotavirus, 2 dose(s) schedule					
<b>8. Programme duration<sup>1</sup>:</b> 2015 -2020					
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)					
	2015-2017	2018	2019	2020	Total <sup>2</sup>
Programme Budget (US\$)	1,561,889 <sup>3</sup>	549,500	591,500	628,500	3,331,389
<b>10. Vaccine introduction grant (in US\$) / Product switch grant:</b> US\$139,000 already disbursed to Liberia on 20 November 2015					
<b>11. Gavi Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>					
<b>Number of vaccines to be purchased with Gavi funds each year</b>	<b>2015-2017</b>	<b>2018</b>			
Rotavirus Routine Programme (doses)		264,000			
Annual Amounts (US\$)	1,561,889 <sup>5</sup>	549,500			

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.																			
<b>13. Self-procurement:</b> Not applicable																			
<p><b>14. Co-financing obligations:</b> Reference code: 1720-LBR-13b-X-C According to the co-financing policy, the Country falls within the group Initial self-financing. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th><b>Number of vaccines to be purchased with Gavi funds each year</b></th> <th><b>2018</b></th> <th><b>2019</b></th> <th><b>2020</b></th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>28,500</td> <td>31,500</td> <td>33,000</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>56,646</td> <td></td> <td></td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>58,500</td> <td>63,000</td> <td>67,000</td> </tr> </tbody> </table>				<b>Number of vaccines to be purchased with Gavi funds each year</b>	<b>2018</b>	<b>2019</b>	<b>2020</b>	Number of vaccine doses	28,500	31,500	33,000	Value of vaccine doses (US\$)	56,646			Total co-financing payments (US\$) (including freight)	58,500	63,000	67,000
<b>Number of vaccines to be purchased with Gavi funds each year</b>	<b>2018</b>	<b>2019</b>	<b>2020</b>																
Number of vaccine doses	28,500	31,500	33,000																
Value of vaccine doses (US\$)	56,646																		
Total co-financing payments (US\$) (including freight)	58,500	63,000	67,000																
<b>15. Operational support for campaigns:</b> Not applicable																			
<b>16. Additional reporting requirements:</b> Not applicable																			
Reports and other information		Due dates																	
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.		15 May 2018																	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.		To be agreed with Secretariat																	
<b>17. Financial clarifications:</b> Not applicable																			
<b>18. Other conditions:</b> Not applicable																			

On behalf of Gavi



Hind Khatib-Othman  
Managing Director, Country Programmes  
14 December 2017